The results indicated that the “Pathways in cancer” and “Proteoglycans in cancer” pathways might be critical for the effect of AYR on CRC, with the core targets identified as AKT1, MYC, TP53, and EGFR (Figure 5B). The gene discussed is TP53; the disease is cancer.